International Leukemia Target Board

The iLTB is a proof-of-concept initiative for children with r/r hematological malignancies, in which available treatment options will be prioritized by actionable events in a harmonized and uniform setting across Europe by a team of biologists, bio-statisticians, bio-informaticians, disease experts, geneticists, flow-experts, clinical trial physicians and also the treating physician. The iLTB will discuss molecular (genetic lesions), immunophenotypic/surface antigen markers information and, if available, drug response profiles to prioritize these events taking into account the treatment history and treatment intention (bridging to hematopoietic stem cell transplanation/CAR-T or palliative) of each patient followed by a registry to monitor how often iLTB advice has been followed, which other therapy was chosen (off-label, compassionate use) and what the patient outcome is at an aggregated level. As such the iLTB is non-interventional as it mainly provides advice and registers data on patients discussed in the iLTB.

NCT Number	NCT05270096
Lead Sponsor	Princess Maxima Center for Pediatric Oncology
Conditions	Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
Enrollment	600 participants
Start Date	2022-12-31
Primary Completion	2030-07-01 (estimated)
Study Completion	2032-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-09